The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma
Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma
November 9th 2017Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab versus ipilimumab for patients with melanoma.
New Adjuvant Therapy Era Builds in Melanoma
Researchers are seeking to determine whether the plethora of new therapies that have been introduced in recent years in the advanced and metastatic settings can benefit patients at risk of recurrence earlier in the treatment timeline for melanoma.
Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma
October 28th 2017Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.